Enhance predictive accuracy, reduce false negatives and late-stage failures for safer drug development with improved preclinical-to-clinical translationRecordings using voltage-sensitive dye (VSD) with quality equivalent to patch-clamp are crucial for assessing cardiovascular risk in drug discovery. They provide a high-fidelity, high-throughput alternative to traditional electrophysiology techniques.
VSD-based recordings offer non-invasive, high-resolution measurements of membrane potential changes across a large number of cells or wells simultaneously, enabling faster and more efficient cardiac safety screening. This approach ensures precise detection of drug-induced effects on cardiac ion channels, such as hERG (IKr), Nav1.5, and Cav1.2, which are critical for evaluating proarrhythmic risk.
The ability to achieve patch-clamp-equivalent data quality using VSD enhances predictive accuracy, reducing false negatives and late-stage failures, and supports safer drug development with improved preclinical-to-clinical translation.
Read more about our hiPSC cardiomyocyte assay.
Development of a robust hNaV1.9 high-throughput screening assay on the Sophion Qube384 platform. This is complemented by a suite of ion channel selectivity assays and sensory neuron recordings to create a versatile screening cascade to support NaV1.9 drug discovery programmes.
Reliable, high-throughput KV7 assays paired with expert interpretation enable faster progression of pain and epilepsy drug discovery programmes.